Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with ...

RAHWAY, N.J., May 31, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy ...

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer. They are given by a healthcare professional as an intravenous (IV) infusion.

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.